Abstract:Zolmitriptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine. There are few reports regarding the in vitro metabolism of zolmitriptan. Previous studies indicated zolmitriptan was metabolized via CYP1A2 in human hepatic microsomes. In order to study the enzyme kinetics and drug interaction, the metabolism of zolmitriptan and possible drug-drug interactions were investigated in rat hepatic microsomes induced with different inducers. An active metabolite, N-demethylzolmitriptan, was detected and another minor, inactive metabolite that was reported in human hepatic microsomes was not detected in this study. The enzyme kinetics for the formation of N-demethylzolmitriptan from zolmitriptan in rat liver microsomes pretreated with BNF were 96+/-22 microM (K(m)), 11+/-3 pmol min(-1)mg protein(-1) (V(max)), and 0.12+/-0.02 microl min(-1)mg protein(-1) (CL(int)). Fluvoxamine and diphenytriazol inhibited zolmitriptan N-demethylase activity catalyzed by CYP1A2 (K(i)=3.8+/-0.3 and 3.2+/-0.1 microM, respectively). Diazepam and propranolol elicited a slight inhibitory effect on the metabolism of zolmitriptan (K(i)=70+/-11 and 90+/-18 microM, respectively). Cimetidine and moclobemide produced no significant effect on the metabolism of zolmitriptan. Fluvoxamine yielded a k(inactivation) value of 0.16 min(-1), and K(i) of 57 microM. The results suggest that rat hepatic microsomes are a reasonable model to study the metabolism of zolmitriptan, although there is a difference in the amount of minor, inactive metabolites between human hepatic microsomes and rat liver microsomes. The results of the inhibition experiments provided information for the interactions between zolmitriptan and drugs co-administrated in clinic, and it is helpful to explain the drug-drug interactions of clinical relevance on enzyme level. This study aso demonstrated that fluvoxamine may be a mechanism-based inactivator of CYP1A2.

Interaction Between Ipriflavone and Other Drugs in Metabolism in Vitro

[Metabolism-Based Interaction of Diphenytriazol and Flavone Compounds].

Drug Interaction of Nifedipine with Ginkgo Flavones in vitro

Differential Effects of Ketoconazole, Fluconazole, and Itraconazole on the Pharmacokinetics of Pyrotinib in Vitro and in Vivo

In Vitro Metabolic Interaction Between Diphenytriazol and Steroid Hormone Drugs

In Vitro Metabolism and Inductive or Inhibitive Effect of DL111 on Rat Cytochrome P4501A Enzyme.

[Glucuronidation and in Vitro Interaction of Ginkgo Flavonoids with Other Drugs].

In Vitro Metabolism of Zolmitriptan in Rat Cytochromes Induced with Β-Naphthoflavone and the Interaction Between Six Drugs and Zolmitriptan

Inhibitory effect of propafenone on vortioxetine metabolism in vitro and in vivo

Metabolic Interactions Between Flumatinib and the CYP3A4 Inhibitors Erythromycin, Cyclosporine, and Voriconazole.

The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline

In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan

Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction

Potential Inhibition of Cytochrome P450 3A4 by Propofol in Human Primary Hepatocytes.

The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro.

Inhibitory Effect of Myricetin on the Pharmacokinetics of Aripiprazole <i>In Vivo</i> and <i>In Vitro</i>

Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro

Difference between in vivo and in vitro effects of propofol on defluorination and metabolic activities of hamster hepatic cytochrome P450-dependent mono-oxygenases.

Bisphenol AF-Propofol Interaction

In vitro metabolism of indiplon and an assessment of its drug interaction potential

Mechanism Underlying Conflicting Drug-Drug Interaction Between Aprepitant and Voriconazole via Cytochrome P450 3A4-Mediated Metabolism